AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa

RecruitingPhase 1, Phase 2Ages 3 Years - 35 YearsAllIsfahan University of Medical Sciences
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Epidermolysis bullosa (EB) is a hereditary disease of skin tissues that causes painful bleeding blisters in the skin and mucous membrane. The prevalence of this disease is 1 in 50,000. The severity of the disease varies depending on the type of disease and may even lead to death. This disease is caused by a genetic mutation in keratin or collagen, and its incidence is the same in all men and women of different human races. In these patients, the skin becomes extremely fragile and peels off with the slightest scratch. Many blisters are one of the most obvious symptoms of this disease. The possibility of skin cancer in people suffering from this disease is more than others. Nowadays, the preference of cell therapy methods is to use biological products produced by cells such as extracellular vesicles and mitochondria instead of stem cells. The use of Extracellular vesicles and engineered E

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * DEB participants determined by electron microscopy, or genetic testing. Individuals with severe DEB (eg, RDEB patients with an absence of collagen VII) and milder forms of DEB (eg, RDEB patients with reduced levels of collagen VII) will be eligible. * People with one or more active wounds (each between 10 and 50 square centimeters on the arms, legs or trunk.) * Participants must be willing to comply with the requirements of the protocol and have consent to participate in the project. * Participants must be negative in the urine drug screening visit. Exclusion Criteria: * Participants with clinical evidence of systemic infection. * Participants have a history of bone marrow transplantation. * Participants must have evidence of autoimmune disease, including insulin-dependent diabetes. * Participant has evidence of significant wound healing prior to treatment (ie, wound closure โ‰ฅ 20% during treatment at the first observation period). * Participant has a severe medical condition, such as malignancy (including skin cancer), life expectancy less than 2 years, which limits movement to the clinical center. * Participants have a current history of alcohol or substance abuse or a history of alcohol or substance abuse that requires treatment in the past 12 months. * People participating in the screening should have a positive hepatitis and human immunodeficiency virus (HIV) test result. * Women who are pregnant, lactating or planning to become pregnant during the study * Women who are of reproductive age and use birth control pills.
๐Ÿ’Š

What it tests

  • Ev.FV 1.0 x 1011 par/ml
๐Ÿ“

Where

1 site
Alzahra Hospital
Isfahan, Iran
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy